Viral Vector and Plasmid DNA Manufacturing Market is estimated to be US$ 2.35 billion by 2030 with a CAGR of 3.9% during the forecast period-By PMI
Prophecy Market Insights latest research report on the Viral Vector and Plasmid DNA Manufacturing Market provides a comprehensive analysis of the current market scenario, growth opportunities, challenges, and emerging trends. The report offers insights into the market’s size and share, key market players, distribution channels, and consumer preferences. It also examines the impact of the COVID-19 pandemic on the market and provides a detailed analysis of the competitive landscape, including strategic alliances, mergers, and acquisitions.
Covina, Sept. 13, 2023 (GLOBE NEWSWIRE) — Viral Vectors and Plasmid DNA have become an important tool used for transferring genetic material into cells. Adenovirus, herpes simplex virus, lentivirus, adeno-associated virus (AAV) are some of the examples of vectors.
Growing prevalence of cancer diseases across globe has given positive impact on market growth. Rising investment in research & development activities in development of gene therapies and emergence of COVID-19 pandemic which has given rise in search of viral vector-based vaccines has provided lucrative opportunities in Viral Vector and Plasmid DNA Manufacturing market growth.
- In May 2023, AGC Biologics launched new “ProntoLVV’ and “BravoAAV” viral vector platforms. The new launched platform includes, in-network plasmid DNA supplies, and has production capacity at different scales up to 2000L and adhesion up to 750L with prequalified scale-down models.
Rising prevalence of diseases and emerging pharmaceutical and biotechnology companies coupled with wide use of vectors in development of advanced therapies has become a major contribution in market growth. Well-developed and advanced research & development institutes in developed countries and presence of major & emerging players is anticipated to increase the demand for Viral Vector and Plasmid DNA Manufacturing market growth.
- Cell and Gene Therapy Catapult
- FinVector Vision Therapies
- Fujifilm Holdings Corporation (Fujifilm Diosynth Biotechnologies)
- SIRION Biotech
- Cobro Biologics
- Merck KGaA
- Oxford Biomedica PLC
- Thermo Fisher Scientific Inc.
- Gilead Company
“Click to receive a sample copy absolutely free”
|Base year for estimation||2022|
|Forecast period||2022 – 2032|
|Market representation||Revenue in USD Billion & CAGR from 2022 to 2032|
|Market Segmentation||By Product Type – Plasmid DNA, Viral Vectors, and Non-viral Vectors
By Application – Cancer, Inherited Disorder, Infectious Diseases, and Other Applications
|Regional scope||North America – U.S., Canada
Europe – UK, Germany, Spain, France, Italy, Russia, Rest of Europe
Asia Pacific – Japan, India, China, South Korea, Australia, Rest of Asia-Pacific
Latin America – Brazil, Mexico, Argentina, Rest of Latin America
Middle East & Africa – South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
|Report coverage||Revenue forecast, company share, competitive landscape, growth factors, and trends|
Market Definition and Segmentation:
The Viral Vector and Plasmid DNA Manufacturing Market involves the production and commercialization of viral vectors and plasmid DNA, which are critical components in gene therapy, gene editing, and vaccine development.
Market segments may include viral vectors (adenovirus, lentivirus, retrovirus, adeno-associated virus, etc.), plasmid DNA, and services related to manufacturing and development.
- Gene Therapy Advancements: Growing interest and investment in gene therapy for treating genetic disorders, cancer, and other diseases are fueling the demand for viral vectors and plasmid DNA.
- Vaccine Development: The COVID-19 pandemic has highlighted the importance of vaccine research, further boosting demand for manufacturing capabilities.
- Gene Editing Technologies: Advancements in CRISPR/Cas9 and other gene editing technologies require efficient delivery systems, driving the need for viral vectors.
- Orphan Diseases: Focus on rare and orphan diseases that can be treated with gene therapies is contributing to target market growth.
- Investment and Funding: Increased funding from governments, pharmaceutical companies, and venture capitalists is supporting research and manufacturing in this sector.
3. Market Challenges:
- Regulatory Hurdles: Stringent regulatory requirements for gene therapy and vaccine manufacturing can pose challenges to market players.
- Production Scalability: Meeting the increasing demand for viral vectors and plasmid DNA while maintaining quality and scalability is a complex challenge.
- Supply Chain Disruptions: The market can be vulnerable to supply chain disruptions, as seen during the COVID-19 pandemic.
- Strategic Partnerships: Collaboration and partnerships between pharmaceutical companies and contract manufacturing organizations (CMOs) for capacity expansion and technology sharing.
- Customized Solutions: Growing interest in tailor-made viral vectors and plasmid DNA to meet specific therapeutic needs.
- Adoption of Single-Use Bioreactors: Increased use of single-use bioreactors for production due to flexibility and reduced risk of contamination.
- Emerging Market Expansion: Expanding manufacturing facilities in emerging markets to reduce production costs.
- Automation and Process Optimization: Adoption of automation and optimization strategies to enhance production efficiency.
The Viral Vector and Plasmid DNA Manufacturing Market is expected to continue its growth trajectory, driven by expanding applications in gene therapy, gene editing, and vaccine development.
Innovations in manufacturing processes, scalability, and regulatory pathways will shape the market’s future.
“Get your hands on a free pdf sample copy by clicking now”
In conclusion, the Viral Vector and Plasmid DNA Manufacturing Market is rapidly evolving, driven by the increasing demand for gene therapy, gene editing, and vaccine development. Key factors include advancements in technology, growing investments, and strategic collaborations. Challenges include regulatory complexities and scalability. The target market’s future appears promising, with continued growth anticipated in the field of genetic medicine and vaccine production.
About Prophecy Market Insights:
Prophecy Market Insights is a leading provider of market research services, offering insightful and actionable reports to clients across various industries. With a team of experienced analysts and researchers, Prophecy Market Insights provides accurate and reliable market intelligence, helping businesses make informed decisions and stay ahead of the competition. The company’s research reports cover a wide range of topics, including industry trends, market size, growth opportunities, competitive landscape, and more. Prophecy Market Insights is committed to delivering high-quality research services that help clients achieve their strategic goals and objectives.
Other related Reports:
- Diagnostic Labs Market Analysis and Forecast by 2023-2030 by recent trends, consumption by regional data, investigation and growth, developments in manufacturing technology and growth Overview.
- Preimplantation Genetic Testing Market By Type (Preimplantation Genetic Screening, Preimplantation Genetic Diagnosis), By Technology (Polymerase Chain Reaction, Next Generation Sequencing, Comparative Genomic Hybridization, Fluorescence In-Situ Hybridization, Single Nucleotide Polymorphism, Validation Biomarkers and Others), By Application (Aneuploidy, Single Gene Disorders, HLA Typing, X-Linked Disorders, and Others), By End-Users (Research Laboratories, Fertility Clinics, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Trends, Analysis and Forecast till 2032
- Oncology Molecular Diagnostics Market Rising prevalence of cancer disease and rate of urbanization is one of the leading factors for the Oncology Molecular Diagnostics Market growth
Follow us on: LinkedIn | Twitter | Facebook |YouTube
CONTACT: Shweta R Prophecy Market Insights U.S.: +1 860 531 2574 APAC: +917775049802 Email- firstname.lastname@example.org Web: www.prophecymarketinsights.com
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.